BOSTON SCIENTIFIC CORPORATION Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
BOSTON SCIENTIFIC CORPORATION (BSX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $258.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2026-02-17
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-12-31 was $0.00.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-09-30 was $0.00.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-06-30 was $220.00M.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-03-31 was $38.00M.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2025 was $258.00M, a 789.66% increase from fiscal 2024.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $29.00M, a 89.38% decline from fiscal 2023.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2023 was $273.00M.
- BOSTON SCIENTIFIC CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $220.00M derived: sum of 3 quarters · filed 2026-02-17 | $258.00M 10-K · filed 2026-02-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $220.00M derived: sum of 2 quarters · filed 2025-11-03 | $258.00M 10-Q · filed 2025-11-03 | $258.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-06-30 | $220.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $258.00M 10-Q · filed 2025-08-01 | $258.00M derived: sum of 3 quarters · filed 2026-02-17 | $258.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-03-31 | $38.00M 10-Q · filed 2025-05-01 | $38.00M derived: sum of 2 quarters · filed 2026-02-17 | $38.00M derived: sum of 3 quarters · filed 2026-02-17 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $29.00M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $29.00M 10-Q · filed 2024-11-01 | ||
| 2024-06-30 | $29.00M 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | $273.00M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $0.00 derived: sum of 3 quarters · filed 2025-02-18 | $0.00 10-K · filed 2025-02-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $56.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $56.00M derived: sum of 3 quarters · filed 2024-02-20 | $219.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $56.00M derived: sum of 2 quarters · filed 2024-02-20 | $219.00M derived: sum of 3 quarters · filed 2024-02-20 | $221.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $56.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $219.00M derived: sum of 2 quarters · filed 2024-02-20 | $221.00M derived: sum of 3 quarters · filed 2024-02-20 | $440.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $163.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $165.00M derived: sum of 2 quarters · filed 2022-11-03 | $384.00M 10-Q · filed 2022-11-03 | $384.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $221.00M 10-Q · filed 2022-08-04 | $221.00M derived: sum of 3 quarters · filed 2023-02-23 | $221.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $219.00M 10-Q · filed 2022-05-05 | $219.00M derived: sum of 2 quarters · filed 2023-02-23 | $219.00M derived: sum of 3 quarters · filed 2023-02-23 | $219.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $0.00 derived: sum of 3 quarters · filed 2022-02-23 | -$4.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-02-23 | -$4.00M derived: sum of 3 quarters · filed 2022-02-23 | $40.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$4.00M derived: sum of 2 quarters · filed 2022-02-23 | $40.00M derived: sum of 3 quarters · filed 2022-02-23 | $127.00M 10-K · filed 2022-02-23 |
| 2019-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $40.00M derived: sum of 2 quarters · filed 2019-11-05 | $127.00M 10-Q · filed 2019-11-05 | $185.00M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $131.00M 10-Q · filed 2019-07-30 | $189.00M derived: sum of 3 quarters · filed 2021-02-23 | |
| 2019-03-31 | $87.00M 10-Q · filed 2019-04-29 | $145.00M derived: sum of 2 quarters · filed 2021-02-23 | ||
| 2018-12-31 | $58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $248.00M 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $190.00M 10-Q · filed 2018-10-29 | |||
| 2017-12-31 | $94.00M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $50.00M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |